Interleukin 6 (IL-6) in serum and urine of renal transplant recipients
- PMID: 3280187
- PMCID: PMC1541438
Interleukin 6 (IL-6) in serum and urine of renal transplant recipients
Abstract
Hybridoma growth factor (HGF) is a 20-25 kD protein, supporting the growth of hybridoma cells in vitro and capable of replacing feeder cells. It was shown to be produced by human monocytes and a number of cultured cell lines. Recently, HGF was found to be identical to interferon-beta 2 or 26 kD protein and BSF-2, and was renamed interleukin 6 (IL-6). Using a sensitive bio-assay we were able to measure IL-6 activity in the serum and urine of healthy volunteers and renal transplant recipients. Low levels of IL-6 were present in the serum but not in the urine of healthy individuals. In contrast, both serum and urine of renal transplant recipients contained high levels of IL-6 directly after transplantation and during acute rejection episodes. On the basis of kinetic studies of the IL-6 response, it is concluded that serial measurement of IL-6, especially in urine, may be of value in monitoring renal transplant recipients. Moreover, the sensitivity of the bioassay will allow for detailed studies as to the biological significance of IL-6 in health and disease.
Similar articles
-
Evaluation of pretransplant serum cytokine levels in renal transplant recipients.Transplant Proc. 2008 Jan-Feb;40(1):92-3. doi: 10.1016/j.transproceed.2007.11.048. Transplant Proc. 2008. PMID: 18261555
-
Induction of hybridoma growth factor (HGF), identical to IL-6, in human fibroblasts by IL-1: use of HGF activity in specific and sensitive biological assays for IL-1 and IL-6.Dev Biol Stand. 1988;69:31-8. Dev Biol Stand. 1988. PMID: 3265677
-
[Monitoring of interleukin-8 in urine and in serum of patients after kidney transplantation].Przegl Lek. 1998;55(11):576-80. Przegl Lek. 1998. PMID: 10216370 Clinical Trial. Polish.
-
High urine sIL-6R as a predictor of late graft failure in renal transplant recipients.Transplantation. 2003 Oct 27;76(8):1190-4. doi: 10.1097/01.TP.0000090345.19569.F3. Transplantation. 2003. PMID: 14578752
-
The value of posttransplant monitoring of interleukin (IL)-2, IL-3, IL-4, IL-6, IL-8, and soluble CD23 in the plasma of renal allograft recipients.Transplantation. 1995 Feb 15;59(3):333-40. Transplantation. 1995. PMID: 7871561
Cited by
-
Pharmacodynamic monitoring of cyclosporin.Clin Pharmacokinet. 1992 Dec;23(6):428-48. doi: 10.2165/00003088-199223060-00004. Clin Pharmacokinet. 1992. PMID: 1458762 Review.
-
Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.Clin Transplant. 2022 Aug;36(8):e14734. doi: 10.1111/ctr.14734. Epub 2022 Jun 12. Clin Transplant. 2022. PMID: 35657013 Free PMC article.
-
Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.Clin Exp Immunol. 1991 Jul;85(1):137-42. doi: 10.1111/j.1365-2249.1991.tb05694.x. Clin Exp Immunol. 1991. PMID: 2070556 Free PMC article.
-
Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus.Rheumatol Int. 1989;8(6):263-8. doi: 10.1007/BF00270982. Rheumatol Int. 1989. PMID: 2471249
-
Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.Cancer Immunol Immunother. 1992;34(5):306-12. doi: 10.1007/BF01741551. Cancer Immunol Immunother. 1992. PMID: 1540977 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical